Ohr Pharmaceutical, Inc. Announces Stockholder Approval of Merger Agreement with NeuBase Therapeutics, Inc.
10 juil. 2019 13h03 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc....
Ohr Pharmaceutical Urges Stockholders to Vote “FOR” Merger with NeuBase Therapeutics at Special Meeting on July 10, 2019
03 juil. 2019 10h00 HE
|
Ohr Pharmaceutical, Inc.
-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal-- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting-- Every...
Ohr Pharmaceutical Reports Financial Results for the Fiscal Second Quarter of 2019
15 mai 2019 16h01 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019....
Ohr Pharmaceutical Regains Compliance with NASDAQ Listing Requirements
21 févr. 2019 10h45 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) today announced that it received notice from The Nasdaq Stock Market LLC indicating that the Company has regained...
Ohr Pharmaceutical Reports Financial Results for the Fiscal First Quarter of 2019
14 févr. 2019 16h05 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three months ended December 31, 2018. “Since we...
Ohr Pharmaceutical Announces Reverse Stock Split to be Effective February 4, 2019
23 janv. 2019 16h30 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty...
Ohr Pharmaceutical, Inc. Announces Merger Agreement with NeuBase Therapeutics, Inc.
03 janv. 2019 06h30 HE
|
Ohr Pharmaceutical, Inc.
Proposed combined company's peptide-nucleic acid antisense oligonucleotide (PATrOL™) technology platform enables rapid development of therapies delivered systemically for genetic diseases Initial...
Ohr Pharmaceutical Reports Fiscal Third Quarter 2018 Financial Results
14 août 2018 16h05 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
Ohr Pharmaceutical Reports Fiscal Second Quarter 2018 Financial Results
15 mai 2018 16h05 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results for its...
Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
14 févr. 2018 16h05 HE
|
Ohr Pharmaceutical, Inc.
NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and...